{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:24:25Z","timestamp":1791919465486,"version":"4.3.4"},"reference-count":165,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T00:00:00Z","timestamp":1559606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004442","name":"National Science Centre","doi-asserted-by":"publisher","award":["Grant 2014\/15\/B\/NZ7\/00947"],"award-info":[{"award-number":["Grant 2014\/15\/B\/NZ7\/00947"]}],"id":[{"id":"10.13039\/501100004442","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Fibroblast growth factor (FGF)\/Fibroblast growth factor receptor (FGFR) signaling regulates various cellular processes during the embryonic development and in the adult organism. In the skin, fibroblasts and keratinocytes control proliferation and survival of melanocytes in a paracrine manner via several signaling molecules, including FGFs. FGF\/FGFR signaling contributes to the skin surface expansion in childhood or during wound healing, and skin protection from UV light damage. Aberrant FGF\/FGFR signaling has been implicated in many disorders, including cancer. In melanoma cells, the FGFR expression is low, probably because of the strong endogenous mutation-driven constitutive activation of the downstream mitogen-activated protein kinase-extracellular signal-regulated kinase (MAPK-ERK) signaling pathway. FGFR1 is exceptional as it is expressed in the majority of melanomas at a high level. Melanoma cells that acquired the capacity to synthesize FGFs can influence the neighboring cells in the tumor niche, such as endothelial cells, fibroblasts, or other melanoma cells. In this way, FGF\/FGFR signaling contributes to intratumoral angiogenesis, melanoma cell survival, and development of resistance to therapeutics. Therefore, inhibitors of aberrant FGF\/FGFR signaling are considered as drugs in combination treatment. The ongoing LOGIC-2 phase II clinical trial aims to find out whether targeting the FGF\/FGFR signaling pathway with BGJ398 may be a good therapeutic strategy in melanoma patients who develop resistance to v-Raf murine sarcoma viral oncogene homolog B (BRAF)\/MEK inhibitors.<\/jats:p>","DOI":"10.3390\/cells8060540","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T09:37:58Z","timestamp":1559727478000},"page":"540","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Fibroblast Growth Factor Receptor Signaling in Skin Cancers"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8279-4742","authenticated-orcid":false,"given":"Malgorzata","family":"Czyz","sequence":"first","affiliation":[{"name":"Department of Molecular Biology of Cancer, Medical University of Lodz, 6\/8 Mazowiecka Street, 92-215 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,6,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Por\u0119bska, N., Latko, M., Kuci\u0144ska, M., Zakrzewska, M., Otlewski, J., and Opali\u0144ski, \u0141. (2018). Targeting Cellular Trafficking of Fibroblast Growth Factor Receptors as a Strategy for Selective Cancer Treatment. J. Clin. Med., 8.","DOI":"10.3390\/jcm8010007"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cytogfr.2005.01.001","article-title":"Cellular signaling by fibroblast growth factor receptors","volume":"16","author":"Eswarakumar","year":"2005","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"950508","DOI":"10.1155\/2012\/950508","article-title":"Alternative Splicing of Fibroblast Growth Factor Receptor IgIII Loops in Cancer","volume":"2012","author":"Holzmann","year":"2012","journal-title":"J. Nucleic Acids"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Latko, M., Czyrek, A., Por\u0119bska, N., Kuci\u0144ska, M., Otlewski, J., Zakrzewska, M., and Opali\u0144ski, \u0141. (2019). Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. Cells, 8.","DOI":"10.3390\/cells8050455"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"a015958","DOI":"10.1101\/cshperspect.a015958","article-title":"Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology","volume":"5","author":"Belov","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1349-7006.2008.00840.x","article-title":"Regulation of growth factor signaling by FRS2 family docking\/scaffold adaptor proteins","volume":"99","author":"Gotoh","year":"2008","journal-title":"Cancer Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/nature08768","article-title":"Signatures of mutation and selection in the cancer genome","volume":"463","author":"Bignell","year":"2010","journal-title":"Nature"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1101\/gr.6522707","article-title":"Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution","volume":"17","author":"Bignell","year":"2007","journal-title":"Genome Res."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Valsesia, A., Rimoldi, D., Martinet, D., Ibberson, M., Benaglio, P., Quadroni, M., Waridel, P., Gaillard, M., Pidoux, M., and Rapin, B. (2011). Network-guided analysis of genes with altered somatic copy number and gene expression reveals pathways commonly perturbed in metastatic melanoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0018369"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1242\/dev.037689","article-title":"FGF signalling: Diverse roles during early vertebrate embryogenesis","volume":"137","author":"Dorey","year":"2010","journal-title":"Development"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"38505","DOI":"10.1074\/jbc.M112.400598","article-title":"Fibroblast growth factor (FGF) signaling during gastrulation negatively modulates the abundance of microRNAs that regulate proteins required for cell migration and embryo patterning","volume":"287","author":"Bobbs","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/carcin\/bgy018","article-title":"FGF2 and EGF induce epithelial-mesenchymal transition in malignant pleural mesothelioma cells via a MAPKinase\/MMP1 signal","volume":"39","author":"Schelch","year":"2018","journal-title":"Carcinogenesis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/annonc\/mdt419","article-title":"Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors","volume":"25","author":"Dienstmann","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: From development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1158\/1078-0432.CCR-14-2329","article-title":"Targeting FGFR Signaling in Cancer","volume":"21","author":"Touat","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.4155\/fmc-2018-0099","article-title":"Making way for suppressing the FGF19\/FGFR4 axis in cancer","volume":"10","author":"Shull","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10555-015-9579-8","article-title":"Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: Biologic and clinical implications","volume":"34","author":"Helsten","year":"2015","journal-title":"Cancer Metastasis Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pcmr.12544","article-title":"Metastatic pathways in patients with cutaneous melanoma","volume":"30","author":"Adler","year":"2017","journal-title":"Pigment Cell Melanoma Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"ref_21","unstructured":"The Cancer Genome Atlas Network (2015). Genomic classification of cutaneous melanoma. Cell, 161, 1681\u20131696."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3941","DOI":"10.2147\/OTT.S117121","article-title":"NRAS-mutant melanoma: Current challenges and future prospect","volume":"10","author":"Adelantado","year":"2017","journal-title":"Onco Targets Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nrclinonc.2017.43","article-title":"Targeted agents and immunotherapies: Optimizing outcomes in melanoma","volume":"14","author":"Luke","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jaad.2017.04.1126","article-title":"The new paradigm of systemic therapies for metastatic melanoma","volume":"77","author":"Volpe","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ejca.2017.06.028","article-title":"Survival of patients with advanced metastatic melanoma: The impact of novel therapies-update 2017","volume":"83","author":"Ugurel","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/jamaoncol.2018.0170","article-title":"Management of Metastatic Melanoma in 2018","volume":"4","author":"Kaufman","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Gatzka, M.V. (2018). Targeted Tumor Therapy Remixed-An Update on the Use of Small-Molecule Drugs in Combination Therapies. Cancers (Basel), 10.","DOI":"10.3390\/cancers10060155"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.cell.2018.04.012","article-title":"An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential","volume":"173","author":"Wang","year":"2018","journal-title":"Cell"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-18-0989","article-title":"Playing the Melanoma Endgame","volume":"24","author":"Teh","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3389\/fonc.2018.00173","article-title":"Microenvironment-Driven Dynamic Heterogeneity and Phenotypic Plasticity as a Mechanism of Melanoma Therapy Resistance","volume":"8","author":"Ahmed","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejca.2016.04.005","article-title":"Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?","volume":"62","author":"Welsh","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1158\/1078-0432.CCR-13-3122","article-title":"BRAF inhibitor resistance mechanisms in metastatic melanoma: Spectrum and clinical impact","volume":"20","author":"Rizos","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1158\/2159-8290.CD-13-0617","article-title":"The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma","volume":"4","author":"Wagle","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.3389\/fonc.2019.00268","article-title":"Diverse Mechanisms of BRAF Inhibitor Resistance in Melanoma Identified in Clinical and Preclinical Studies","volume":"9","author":"Luebker","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1056\/NEJMc1902228","article-title":"Estimation of Distant Metastasis-free Survival in Trials of Adjuvant Therapy for Melanoma","volume":"380","author":"Eggermont","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1517\/14728222.2011.566217","article-title":"Targeting fibroblast-growth-factor-receptor-dependent signaling for cancer therapy","volume":"15","author":"Heinzle","year":"2011","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2302\/kjm.44.9","article-title":"Current update and trends in melanin pigmentation and melanin biology","volume":"44","author":"Jimbow","year":"1995","journal-title":"Keio J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1087-0024.2005.200407.x","article-title":"Normal human melanocyte homeostasis as a paradigm for understanding melanoma","volume":"10","author":"Haass","year":"2005","journal-title":"J. Investig. Dermatol. Symp. Proc."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1083\/jcb.107.4.1611","article-title":"Basic fibroblast growth factor from human keratinocytes is a natural mitogen for melanocytes","volume":"107","author":"Halaban","year":"1988","journal-title":"J. Cell. Biol."},{"key":"ref_42","first-page":"177","article-title":"bFGF as an autocrine growth factor for human melanomas","volume":"3","author":"Halaban","year":"1988","journal-title":"Oncogene Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/BF02631248","article-title":"Human dermal fibroblasts express multiple bFGF and aFGF proteins","volume":"27A","author":"Root","year":"1991","journal-title":"In Vitro Cell. Dev. Biol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1203066","article-title":"Basic fibroblast growth factor induces a transformed phenotype in normal human melanocytes","volume":"18","author":"Nesbit","year":"1999","journal-title":"Oncogene"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S0002-9440(10)64041-2","article-title":"Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin","volume":"158","author":"Berking","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1158\/0008-5472.CAN-03-3438","article-title":"Induction of melanoma phenotypes in human skin by growth factors and ultraviolet B","volume":"64","author":"Berking","year":"2004","journal-title":"Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1046\/j.1523-1747.1999.00636.x","article-title":"FGF expression allows nevus cells to survive in three-dimensional collagen gel under conditions that induce apoptosis in normal human melanocytes","volume":"113","author":"Alanko","year":"1999","journal-title":"J. Invest. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0046-8177(84)80310-X","article-title":"A study of tumor progression: The precursor lesions of superficial spreading and nodular melanoma","volume":"15","author":"Clark","year":"1984","journal-title":"Hum. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1111\/1523-1747.ep12465203","article-title":"Localization of basic fibroblast growth factor mRNA in melanocytic lesions by in situ hybridization","volume":"96","author":"Scott","year":"1991","journal-title":"J. Invest. Dermatol."},{"key":"ref_50","first-page":"329","article-title":"Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridisation. Implications for tumor progression","volume":"144","author":"Reed","year":"1994","journal-title":"Am. J. Pathol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/00008390-199908000-00006","article-title":"Expression of basic fibroblast growth factor and vascular endothelial factor in primary and metastatic melanoma from the same patients","volume":"9","author":"Birck","year":"1999","journal-title":"Melanoma Res."},{"key":"ref_52","first-page":"2205","article-title":"Development of invasive and growth factor-independent cell variants from primary human melanomas","volume":"51","author":"Kath","year":"1991","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00008390-199708000-00004","article-title":"Expression of fibroblast growth factor receptors in naevus-cell naevus and malignant melanoma","volume":"7","author":"Ahmed","year":"1997","journal-title":"Melanoma Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1600-0560.2006.00569.x","article-title":"Protein expression of melanocyte growth factors (bFGF, SCF) and their receptors (FGFR-1, c-kit) in nevi and melanoma","volume":"34","author":"Giehl","year":"2007","journal-title":"J. Cutan. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF02623492","article-title":"bFGF is the putative natural growth factor for human melanocytes","volume":"23","author":"Halaban","year":"1987","journal-title":"In Vitro Cell. Dev. Biol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1111\/j.1749-6632.1988.tb18805.x","article-title":"Paracrine stimulation of melanocytes by keratinocytes through basic fibroblast growth factor","volume":"548","author":"Halaban","year":"1988","journal-title":"Ann. NY Acad. Sci."},{"key":"ref_57","first-page":"4815","article-title":"Induction of growth factor RNA expression in human malignant melanoma: Markers of transformation","volume":"51","author":"Albino","year":"1991","journal-title":"Cancer Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1600-0560.1996.tb01442.x","article-title":"The prognostic significance of basic fibroblast growth factor in cutaneous malignant melanoma","volume":"23","author":"Barnhill","year":"1996","journal-title":"J. Cutan. Pathol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1600-0560.1996.tb01284.x","article-title":"Expression of basic fibroblast growth factor in desmoplastic melanoma","volume":"23","author":"Carlson","year":"1996","journal-title":"J. Cutan. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1034\/j.1600-0625.2003.120310.x","article-title":"Fibroblast growth factor-2 but not Mel-CAM and\/or beta3 integrin promotes progression of melanocytes to melanoma","volume":"12","author":"Meier","year":"2003","journal-title":"Exp. Dermatol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Zalesna, I., Osrodek, M., Hartman, M.L., Rozanski, M., Sztiller-Sikorska, M., Niewinna, K., Nejc, D., and Czyz, M. (2017). Exogenous growth factors bFGF, EGF and HGF do not influence viability and phenotype of V600EBRAF melanoma cells and their response to vemurafenib and trametinib in vitro. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183498"},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Czyz, M. (2018). HGF\/c-MET Signaling in Melanocytes and Melanoma. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123844"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s12253-015-9916-9","article-title":"Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations","volume":"21","author":"Garay","year":"2015","journal-title":"Pathol. Oncol. Res."},{"key":"ref_64","first-page":"6571","article-title":"Enhanced expression of the tie receptor tyrosine kinase mesenger RNA in the vascular endothelium of metastatic melanomas","volume":"54","author":"Kaipainen","year":"1994","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nm0897-887","article-title":"Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth","volume":"3","author":"Wang","year":"1997","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1002\/j.1460-2075.1989.tb08543.x","article-title":"Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor","volume":"8","author":"Becker","year":"1989","journal-title":"EMBO J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0002-9440(10)64719-0","article-title":"Human melanoma progression in skin reconstructs: Biological significance of bFGF","volume":"156","author":"Meier","year":"2000","journal-title":"Am. J. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/sj.onc.1201159","article-title":"Suppression of autocrine cell proliferation and tumorigenesis of human melanoma cells and fibroblast growth factor transformed fibroblasts by a kinase deficient FGF receptor 1: Evidence for the involvement of Src-family kinases","volume":"14","author":"Yayon","year":"1997","journal-title":"Oncogene"},{"key":"ref_69","first-page":"2303","article-title":"Inhibition of the fibroblast growth factor receptor 1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation","volume":"7","author":"Becker","year":"1992","journal-title":"Oncogene"},{"key":"ref_70","first-page":"7282","article-title":"Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor","volume":"61","author":"Graeven","year":"2001","journal-title":"Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF03402080","article-title":"Noninvasive dynamic fluorescence imaging of human melanomas reveals that targeted inhibition of bFGF or FGFR-1 in melanoma cells blocks tumor growth by apoptosis","volume":"8","author":"Valesky","year":"2002","journal-title":"Mol. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00008390-200402000-00003","article-title":"Inhibition of proliferation and survival of melanoma cells by adenoviral-mediated expression of dominant negative fibroblast growth factor receptor","volume":"14","author":"Ozen","year":"2004","journal-title":"Melanoma Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/jid.2011.177","article-title":"Fibroblast growth factor receptors as therapeutic targets in human melanoma: Synergism with BRAF inhibition","volume":"131","author":"Metzner","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"87750","DOI":"10.18632\/oncotarget.21184","article-title":"FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo","volume":"8","author":"Ghassemi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e9081","DOI":"10.15252\/emmm.201809081","article-title":"Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma","volume":"11","author":"Chua","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0002-9440(10)64922-X","article-title":"Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor\/fibroblast growth factor receptor-1 and ephrin-A1\/EphA2 on melanoma progression","volume":"160","author":"Straume","year":"2002","journal-title":"Am. J. Pathol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1083\/jcb.141.7.1659","article-title":"Fibroblast growth factor-2 (FGF-2) induces vascular endothelial growth factor (VEGF) expression in the endothelial cells of forming capillaries: An autocrine mechanism contributing to angiogenesis","volume":"141","author":"Seghezzi","year":"1998","journal-title":"J. Cell. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1349-7006.2007.00432.x","article-title":"Fibroblast growth factor-2-induced host stroma reaction during initial tumor growth promotes progression of mouse melanoma via vascular endothelial growth factor A-dependent neovascularization","volume":"98","author":"Tsunoda","year":"2007","journal-title":"Cancer Sci."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Sonveaux, P., Copetti, T., De Saedeleer, C.J., V\u00e9gran, F., Verrax, J., Kennedy, K.M., Moon, E.J., Dhup, S., Danhier, P., and Fr\u00e9rart, F. (2012). Targeting the lactate transporter MCT1 in endothelial cells inhibits lactate-induced HIF-1 activation and tumor angiogenesis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0033418"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2152\/jmi.61.7","article-title":"Molecular tumorigenesis of the skin","volume":"61","author":"Kubo","year":"2014","journal-title":"J. Med. Invest."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/hmg\/ddi127","article-title":"Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans","volume":"14","author":"Rosty","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/modpathol.3800837","article-title":"FGFR3 mutations in seborrheic keratoses are already present in flat lesions and associated with age and localization","volume":"20","author":"Hafner","year":"2007","journal-title":"Mod. Pathol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"20780","DOI":"10.1073\/pnas.1008365107","article-title":"Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors","volume":"107","author":"Hafner","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1172\/JCI38543","article-title":"A positive FGFR3\/FOXN1 feedback loop underlies benign skin keratosis versus squamous cell carcinoma formation in humans","volume":"119","author":"Mandinova","year":"2009","journal-title":"J. Clin. Invest."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.4161\/cc.28492","article-title":"Activating FGFR3 mutations cause mild hyperplasia in human skin, but are insufficient to drive benign or malignant skin tumors","volume":"13","author":"Duperret","year":"2014","journal-title":"Cell Cycle"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.celrep.2014.01.045","article-title":"Pten loss induces autocrine FGF signaling to promote skin tumorigenesis","volume":"6","author":"Mathew","year":"2014","journal-title":"Cell Rep."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/sj.emboj.7601583","article-title":"The role of fibroblast growth factor receptor 2b in skin homeostasis and cancer development","volume":"26","author":"Grose","year":"2007","journal-title":"EMBO J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"13156","DOI":"10.1073\/pnas.1604450113","article-title":"Targeting of Ras-mediated FGF signaling suppresses Pten-deficient skin tumor","volume":"113","author":"Mathew","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1067\/mjd.2000.104792","article-title":"Altered basic fibroblast growth factor expression in common epidermal neoplasms: Examination with in situ hybridization and immunohistochemistry","volume":"42","author":"Arbiser","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.0022-202X.2004.23497.x","article-title":"Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK\/STAT3 and PI3-kinase\/Akt pathways","volume":"123","author":"Jee","year":"2004","journal-title":"J. Invest. Dermatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3109\/09546634.2010.551108","article-title":"Efficacy of the fibroblast growth factor inhibitor 2,5-dihydroxyphenylsulfonate in basal cell carcinoma: A histopathological and inmunohistochemical study","volume":"22","author":"Cuevas","year":"2011","journal-title":"J. Dermatolog. Treat."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.12.016","article-title":"Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival","volume":"91","author":"Dubot","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/bjc.2014.229","article-title":"Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer","volume":"110","author":"Cihoric","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_98","first-page":"803","article-title":"Prognostic value of FGFR1 gene copy number in patients with non-small cell lung cancer: A meta-analysis","volume":"6","author":"Yang","year":"2014","journal-title":"J. Thorac. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1245\/s10434-013-3456-x","article-title":"Low prognostic implication of fibroblast growth factor family activation in triple-negative breast cancer subsets","volume":"21","author":"Lee","year":"2014","journal-title":"Ann. Surg. Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/bjc.2011.603","article-title":"FGFR2 gene amplification and clinicopathological features in gastric cancer","volume":"106","author":"Matsumoto","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature25171","article-title":"A metabolic function of FGFR3-TACC3 gene fusions in cancer","volume":"553","author":"Frattini","year":"2018","journal-title":"Nature"},{"key":"ref_103","first-page":"855","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"71","DOI":"10.23838\/pfm.2018.00044","article-title":"FGFR3-TACC3: A novel gene fusion in malignant melanoma","volume":"2","author":"Lee","year":"2018","journal-title":"Precis. Future Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"36639","DOI":"10.18632\/oncotarget.16698","article-title":"Genetic alterations in seborrheic keratoses","volume":"8","author":"Heidenreich","year":"2017","journal-title":"Oncotarget"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1038\/sj.jid.5700422","article-title":"High frequency of FGFR3 mutations in adenoid seborrheic keratoses","volume":"126","author":"Hafner","year":"2006","journal-title":"J. Invest. Dermatol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.4161\/cc.5.23.3509","article-title":"FGFR3 mutations in benign skin tumors","volume":"5","author":"Hafner","year":"2006","journal-title":"Cell Cycle"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/(SICI)1096-8628(19990702)85:1<53::AID-AJMG10>3.0.CO;2-F","article-title":"Severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN): Phenotypic analysis of a new skeletal dysplasia caused by a Lys650Met mutation in fibroblast growth factor receptor 3","volume":"85","author":"Bellus","year":"1999","journal-title":"Am. J. Med. Genet."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/pde.13748","article-title":"Acanthosis nigricans, hypochondroplasia, and FGFR3 mutations: Findings with five new patients, and a review of the literature","volume":"36","author":"Aubert","year":"2019","journal-title":"Pediatr. Dermatol."},{"key":"ref_110","first-page":"30","article-title":"Effective treatment of a platinum-resistant cutaneous squamous cell carcinoma case by EGFR pathway inhibition","volume":"9","author":"Capalbo","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.yexcr.2004.11.012","article-title":"Cell responses to FGFR3 signalling: Growth, differentiation and apoptosis","volume":"304","author":"Knowles","year":"2005","journal-title":"Exp. Cell Res."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1172\/JCI28163","article-title":"Mosaicism of activating FGFR3 mutations in human skin causes epidermal nevi","volume":"116","author":"Hafner","year":"2006","journal-title":"J. Clin. Invest."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/1541-7786.MCR-13-0006","article-title":"Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14 ARF and RAR\u03b2 signaling","volume":"11","author":"Dahl","year":"2013","journal-title":"Mol. Cancer Res."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"7182","DOI":"10.1073\/pnas.121183798","article-title":"Structural basis for fibroblast growth factor receptor 2 activation in Apert syndrome","volume":"98","author":"Ibrahimi","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/hmg\/ddh235","article-title":"Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities","volume":"13","author":"Ibrahimi","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"ref_116","first-page":"840","article-title":"Cancer progression and tumor cell motility are associated with the FGFR4 Arg388 allele","volume":"62","author":"Bange","year":"2002","journal-title":"Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/j.ctrv.2014.08.003","article-title":"Prognostic relevance of receptor tyrosine kinase expression in breast cancer: A meta-analysis","volume":"40","author":"Templeton","year":"2014","journal-title":"Cancer Treat. Rev."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1038\/sj.bjc.6603181","article-title":"FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients","volume":"94","author":"Streit","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/mc.22953","article-title":"Whole-exome sequencing reveals novel genetic variants associated with diverse phenotypes of melanoma cells","volume":"58","author":"Hartman","year":"2019","journal-title":"Mol. Carcinog."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature16449","article-title":"Germline variant FGFR4 p.G388R exposes a membrane-proximal STAT3 binding site","volume":"528","author":"Ulaganathan","year":"2015","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/13816128113199990594","article-title":"Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?","volume":"20","author":"Heinzle","year":"2014","journal-title":"Curr. Pharm. Des."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1158\/1541-7786.MCR-08-0021","article-title":"Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma","volume":"7","author":"Gartside","year":"2009","journal-title":"Mol. Cancer Res."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/138920209788488526","article-title":"Molecular markers of tumor progression in melanoma","volume":"10","author":"Rother","year":"2009","journal-title":"Curr. Genomics"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1200\/JCO.2010.33.2312","article-title":"Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling","volume":"29","author":"Wagle","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"471","DOI":"10.5604\/17322693.1201719","article-title":"BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma","volume":"70","author":"Hartman","year":"2016","journal-title":"Postepy Hig. Med. Dosw."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1158\/2159-8290.CD-17-0401","article-title":"Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation","volume":"7","author":"Song","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nature24040","article-title":"PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas","volume":"550","author":"Lu","year":"2017","journal-title":"Nature"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature09626","article-title":"Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation","volume":"468","author":"Nazarian","year":"2010","journal-title":"Nature"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1038\/ncomms6712","article-title":"Low MITF\/AXL ratio predicts early resistance to multiple targeted drugs in melanoma","volume":"5","author":"Krijgsman","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1093\/annonc\/mdu049","article-title":"Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition","volume":"25","author":"Turajlic","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nature11183","article-title":"Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion","volume":"487","author":"Straussman","year":"2012","journal-title":"Nature"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1038\/s41388-018-0205-4","article-title":"AXL\/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma","volume":"37","author":"Zuo","year":"2018","journal-title":"Oncogene"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Chan, X.Y., Singh, A., Osman, N., and Piva, T.J. (2017). Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18071527"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/onc.2013.34","article-title":"Targeted therapy for melanoma: Rational combinatorial approaches","volume":"33","author":"Kwong","year":"2014","journal-title":"Oncogene"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ccr.2010.11.023","article-title":"Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R\/PI3K","volume":"18","author":"Villanueva","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature11249","article-title":"Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors","volume":"487","author":"Wilson","year":"2012","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1593\/neo.111102","article-title":"Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032","volume":"13","author":"Vergani","year":"2011","journal-title":"Neoplasia"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ccr.2012.10.009","article-title":"Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas","volume":"22","author":"Lito","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00008390-199606000-00005","article-title":"Expression of FGF1 and FGFR1 in human melanoma tissues","volume":"6","author":"Xerri","year":"1996","journal-title":"Melanoma Res."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature22794","article-title":"Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance","volume":"546","author":"Shaffer","year":"2017","journal-title":"Nature"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41389-018-0082-2","article-title":"BRAF inhibition causes resilience of melanoma cell lines by inducing the secretion of FGF1","volume":"7","author":"Grimm","year":"2018","journal-title":"Oncogenesis"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1755-148X.2011.00950.x","article-title":"Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition","volume":"25","author":"Deng","year":"2012","journal-title":"Pigment. Cell Melanoma Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5067","DOI":"10.1158\/0008-5472.CAN-11-0140","article-title":"Combinatorial treatments that overcome PDGFR\u03b2-driven resistance of melanoma cells to V600EB-RAF inhibition","volume":"71","author":"Shi","year":"2011","journal-title":"Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"28087","DOI":"10.1074\/jbc.M112.377218","article-title":"Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)\/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma","volume":"287","author":"Yadav","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/bjc.2012.103","article-title":"Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells","volume":"106","author":"Queralt","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CMR.0000000000000085","article-title":"Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment","volume":"24","author":"Mak","year":"2014","journal-title":"Melanoma Res."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jphotobiol.2018.06.005","article-title":"Ultraviolet radiation-mediated development of cutaneous melanoma: An update","volume":"185","author":"Emri","year":"2018","journal-title":"J. Photochem. Photobiol. B."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0025-6196(11)61033-1","article-title":"Malignant melanoma in the 21st century, part 1: Epidemiology, risk factors, screening, prevention, and diagnosis","volume":"82","author":"Markovic","year":"2007","journal-title":"Mayo Clin. Proc."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10552-007-0123-1","article-title":"A comparison of the anatomic distribution of cutaneous melanoma in two populations with different levels of sunlight: The west of Scotland and Queensland, Australia 1982-2001","volume":"18","author":"Whiteman","year":"2007","journal-title":"Cancer Causes Control."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/jid.2014.425","article-title":"The genomic landscape of childhood and adolescent melanoma","volume":"135","author":"Lu","year":"2015","journal-title":"J. Invest. Dermatol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S2352-4642(19)30005-7","article-title":"MC1R variants in childhood and adolescent melanoma: A retrospective pooled analysis of a multicentre cohort","volume":"3","author":"Pellegrini","year":"2019","journal-title":"Lancet Child. Adolesc. Health"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jid.2015.12.007","article-title":"Prediction of Melanoma Risk in a Southern European Population Based on a Weighted Genetic Risk Score","volume":"136","author":"Kypreou","year":"2016","journal-title":"J. Invest. Dermatol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.jid.2018.05.023","article-title":"Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies","volume":"138","author":"Cust","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Taylor, N.J., Mitra, N., Qian, L., Avril, M.F., Bishop, D.T., Paillerets, B.B., Bruno, W., Calista, D., Cuellar, F., and Cust, A.E. (2019). Estimating CDKN2A mutation carrier probability among global familial melanoma cases using GenoMELPREDICT. J. Am. Acad. Dermatol.","DOI":"10.1016\/j.jaad.2019.01.079"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41467-018-08078-w","article-title":"Novel pleiotropic risk loci for melanoma and nevus density implicate multiple biological pathways","volume":"10","author":"Duffy","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"Nan, H., Qureshi, A.A., Hunter, D.J., and Han, J. (2009). Genetic variants in FGFR2 and FGFR4 genes and skin cancer risk in the Nurses\u2019 Health Study. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-172"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2010.149","article-title":"Biomarkers: The useful and the not so useful\u2014An assessment of molecular prognostic markers for cutaneous melanoma","volume":"130","author":"Rimm","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1042\/BST20180004","article-title":"Structure, activation and dysregulation of fibroblast growth factor receptor kinases: Perspectives for clinical targeting","volume":"46","author":"Farrell","year":"2018","journal-title":"Biochem. Soc. Trans."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Lang, L., and Teng, Y. (2019). Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Cells, 8.","DOI":"10.3390\/cells8010031"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-14-3063","article-title":"Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma","volume":"21","author":"Hong","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","article-title":"Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study","volume":"35","author":"Nogova","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/6\/540\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:56:13Z","timestamp":1760187373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/6\/540"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,4]]},"references-count":165,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6]]}},"alternative-id":["cells8060540"],"URL":"https:\/\/doi.org\/10.3390\/cells8060540","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,4]]}}}